S'abonner

Prenatal and infant acetaminophen exposure, antioxidant gene polymorphisms, and childhood asthma - 07/08/11

Doi : 10.1016/j.jaci.2010.08.047 
Seif O. Shaheen, PhD a, , Roger B. Newson, DPhil a, Susan M. Ring, PhD b, Matthew J. Rose-Zerilli, BSc d, John W. Holloway, PhD d, A. John Henderson, MD c
a Respiratory Epidemiology and Public Health Group, National Heart and Lung Institute, Imperial College London, London, United Kingdom 
b Department of Social Medicine, University of Bristol, Bristol, United Kingdom 
c Department of Community-based Medicine, University of Bristol, Bristol, United Kingdom 
d Respiratory Genetics Group, Division of Infection, Inflammation and Immunity and Division of Human Genetics, University of Southampton, Southampton, United Kingdom 

Reprint requests: Seif O. Shaheen, PhD, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Centre for Health Sciences, Barts and The London School of Medicine and Dentistry, 2 Newark Street, Whitechapel, London, E1 2AT, United Kingdom.

Abstract

Background

Prenatal and infant acetaminophen exposure has been associated with an increased risk of childhood asthma phenotypes. Demonstration of biologically plausible interactions between these exposures and maternal and child antioxidant gene polymorphisms would strengthen causal inference.

Objective

To explore potential interactions between prenatal and infant acetaminophen exposure and antioxidant genotypes on childhood asthma.

Methods

In the Avon Longitudinal Study of Parents and Children, we typed a functional nuclear erythroid 2 p45-related factor 2 (Nrf2) polymorphism and glutathione S-transferase (GST) M1, T1, and P1 polymorphisms. Effects of prenatal and infant acetaminophen exposure on asthma phenotypes at 7 years were stratified by genotype in >4000 mothers and >5000 children.

Results

Risk of asthma and wheezing associated with early gestation acetaminophen exposure was increased when maternal copies of the minor T allele of Nrf2 were present (P interactions, .02 and .04, respectively). Risk of asthma associated with late gestation exposure was higher when maternal GSTT1 genotype was present rather than absent (P interaction, .006), and risk of wheezing was increased when maternal GSTM1 was present (P interaction, .04). Although acetaminophen use in infancy was associated with an increased risk of atopy, child antioxidant genotype did not modify associations between infant acetaminophen use and asthma phenotypes. However, the increased risk of asthma and wheezing associated with late gestation acetaminophen exposure in the presence of maternal GSTM1 was further enhanced when GSTM1 was also present in the child.

Conclusion

Maternal antioxidant gene polymorphisms may modify the relation between prenatal acetaminophen exposure and childhood asthma, strengthening evidence for a causal association. In contrast, relations between infant acetaminophen use and asthma and atopy were not modified by child genotype and may be confounded by pre-existing wheeze or allergy.

Le texte complet de cet article est disponible en PDF.

Key words : Asthma, acetaminophen, paracetamol, glutathione-S-transferase, Nrf2, prenatal exposure, delayed effects, ALSPAC, pregnancy, birth cohort, genotype, gene-environment interaction

Abbreviations used : ALSPAC, BMI, BR, FEF25-75, FVC, GST, NAPQI, Nrf2, OR, SNP


Plan


 The UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children. This study was funded by the British Lung Foundation. S.O.S. was an Asthma UK Senior Research Fellow.
 Disclosure of potential conflict of interest: S. O. Shaheen receives research support from Asthma UK and the Medical Research Council. R. B. Newson receives compensation from the UK Department of Health Policy Research Programme. S. M. Ring receives research support from the Wellcome Trust, the Medical Research Council, and the European Union. J. W. Holloway receives research support from the Medical Research Council UK and Asthma UK. A. J. Henderson receives research support from the Medical Research Council UK and the Wellcome Trust. M. J. Rose-Zerilli has declared that he has no conflict of interest.


© 2010  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 126 - N° 6

P. 1141 - décembre 2010 Retour au numéro
Article précédent Article précédent
  • Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma
  • Wendy Gould, Edward L. Peterson, Gloria Karungi, Amanda Zoratti, John Gaggin, Ghazwan Toma, Shiqing Yan, Albert M. Levin, James J. Yang, Karen Wells, Mingqun Wang, Robert R. Burke, Kenneth Beckman, Danijela Popadic, Susan J. Land, Rajesh Kumar, Max A. Seibold, David E. Lanfear, Esteban G. Burchard, L. Keoki Williams
| Article suivant Article suivant
  • Racial differences in biologic predictors of severe asthma: Data from the Severe Asthma Research Program
  • Christy Gamble, Evelyn Talbott, Ada Youk, Fernando Holguin, Bruce Pitt, Lori Silveira, Eugene Bleecker, William Busse, William Calhoun, Mario Castro, Kian Fan Chung, Serpil Erzurum, Elliot Israel, Sally Wenzel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.